Literature DB >> 7910816

Taxol and ionizing radiation: interaction and mechanisms.

T K Hei1, C Q Piao, C R Geard, E J Hall.   

Abstract

PURPOSE: Taxol has been shown to be clinically active against several types of human tumors. To assess the potential oncogenic effect of taxol, the in vitro cytotoxic and oncogenic transforming effects of taxol, either alone or in combination with gamma-irradiation, were examined. METHODS AND MATERIALS: Exponentially growing mouse C3H 10T1/2 cells were treated with taxol with or without concurrent gamma-irradiation. After treatment, cultures were replated for both clonogenic survival and transformation assays. To determine the effects of taxol on cell cycle kinetics, treated cells were concurrently labelled with bromodeoxyuridine coupled with fluorescein. Accumulated mitotic cells were isolated by the shake-off technique and their plating efficiency and radiosensitivity were determined.
RESULTS: Taxol induced a dose dependent toxicity in 10T1/2 cells. In contrast to human tumor cells in culture, the mitotic block induced by a 100 nM dose of taxol in 10T1/2 cells was only partial. While taxol was ineffective in transformant induction, it enhanced the oncogenic transforming potential of gamma-rays in a supra-additive manner. The fact that approximately 15% of taxol-induced mitotic cells were clonogenically viable and at a cell cycle stage that was most radiosensitive suggests a mechanistic basis for the observed enhancement in transformation incidence by ionizing radiation.
CONCLUSION: Taxol enhances the oncogenicity of radiation by partially blocking the 10T1/2 cells in G2/M phases of the cell cycle, phases that are most sensitive to radiation induced oncogenic transformation.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  1994        PMID: 7910816     DOI: 10.1016/0360-3016(94)90273-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

Review 1.  [Radiobiological mechanisms for new strategies in radiochemotherapy].

Authors:  K R Trott
Journal:  Strahlenther Onkol       Date:  1998-08       Impact factor: 3.621

2.  Radiation and concomitant weekly administration of paclitaxel in patients with glioblastoma multiforme. A phase II study.

Authors:  G Fountzilas; A Karavelis; A Capizzello; A Kalogera-Fountzila; G Karkavelas; N Zamboglou; P Selviaridis; G Foroglou; A Tourkantonis
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

3.  A phase II study of weekly paclitaxel, cisplatin and concurrent radiation therapy for locally-advanced unresectable non-small cell lung cancer: early closure due to lack of efficacy.

Authors:  Se Hoon Park; Mi Kyung Kim; Sun Young Kyung; Young-Hee Lim; Chang Hyeok An; Jeong Woong Park; Seong Hwan Jeong; Jae Woong Lee; Kyu Chan Lee; Eun Kyung Cho; Soo Mee Bang; Dong Bok Shin; Jae Hoon Lee
Journal:  Cancer Res Treat       Date:  2004-10-31       Impact factor: 4.679

4.  Radiosensitizing effect of epothilone B on human epithelial cancer cells.

Authors:  T Baumgart; G Klautke; S Kriesen; S A Kuznetsov; D G Weiss; R Fietkau; G Hildebrandt; K Manda
Journal:  Strahlenther Onkol       Date:  2012-01-12       Impact factor: 3.621

5.  The combination of gamma ionizing radiation and 8-Cl-cAMP induces synergistic cell growth inhibition and induction of apoptosis in human prostate cancer cells.

Authors:  Vesna Vucić; Ana Nićiforović; Miroslav Adzić; Marija B Radojcić; Sabera Ruzdijić
Journal:  Invest New Drugs       Date:  2007-12-04       Impact factor: 3.850

6.  Phase I study of concurrent and consolidation cisplatin and docetaxel chemotherapy with thoracic radiotherapy in non-small cell lung cancer.

Authors:  T W Zhang; G B Rodrigues; A V Louie; D Palma; A R Dar; B Dingle; W Kocha; M Sanatani; B Yaremko; E Yu; J Younus; M D Vincent
Journal:  Curr Oncol       Date:  2018-02-28       Impact factor: 3.677

7.  Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma.

Authors:  Lara Barazzuol; Raj Jena; Neil G Burnet; Lisiane B Meira; Jonathan C G Jeynes; Karen J Kirkby; Norman F Kirkby
Journal:  Radiat Oncol       Date:  2013-03-19       Impact factor: 3.481

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.